Nektar Therapeutics (NKTR) Stock Price, News & Analysis

Company Overview

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that harness the body’s immune system to treat cancer and autoimmune and inflammatory diseases. The company’s research is centered on cytokine biology, immune-cell regulation and its proprietary polymer-conjugation technologies, which are designed to modify therapeutic compounds and potentially improve their duration, delivery or tolerability.

Nektar’s pipeline has included investigational therapies such as rezpegaldesleukin, an immune-modulating treatment being studied for autoimmune and inflammatory conditions. The company has also developed drug candidates for oncology and has historically advanced products through collaborations with larger pharmaceutical companies. Its technology has contributed to partnered and approved medicines, including the opioid-induced constipation treatment Movantik, which was developed with AstraZeneca.

Founded in 1990 and headquartered in San Francisco, California, Nektar has worked with pharmaceutical partners and conducted development activities across international markets. Howard W. Robin has served as the company’s president and chief executive officer for many years. Nektar’s business is primarily focused on research and clinical development, with commercialization and distribution of partnered products generally handled through collaboration agreements.

Key Stats

• Today's Range: $68.35 to $71.41
• 50-Day Range: $64.84 to $76.48
• 52-Week Range: $33.40 to $109.00
• Volume: 784,031 shs
• Average Volume: 573,682 shs
• Market Capitalization: $2.38 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $141.50
• Consensus Rating: Moderate Buy

Nektar Therapeutics Stock Analysis - MarketRank™

Nektar Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 509th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Nektar Therapeutics has a consensus price target of $141.50, representing about 102.8% upside from its current price of $69.76.

Amount of Analyst Coverage

Nektar Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($8.28) to ($11.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nektar Therapeutics is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nektar Therapeutics is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nektar Therapeutics has a P/B Ratio of 15.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.23% of the float of Nektar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nektar Therapeutics has a short interest ratio ("days to cover") of 11.45, which indicates bearish sentiment.

Change versus previous month

Short interest in Nektar Therapeutics has recently decreased by 1.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nektar Therapeutics does not currently pay a dividend.

Dividend Growth

Nektar Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.86

News Sentiment

Nektar Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Nektar Therapeutics this week, compared to 10 articles on an average week.

Search Interest

5 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,380,558.00 in company stock.

Percentage Held by Insiders

2.50% of the stock of Nektar Therapeutics is held by insiders.

Percentage Held by Institutions

75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NKTR
• CIK: 906709
• Web: www.nektar.com
• Phone: (415) 482-5300
• Fax: 415-339-5300
• Employees: 63
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Nektar Therapeutics: $141.50
• High Price Target: $192.00
• Low Price Target: $65.00
• Potential Upside/Downside: +102.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$164.08 million
• Net Margins: -287.84%
• Pretax Margin: -280.48%
• Return on Equity: -37.87%
• Return on Assets: -25.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.42
• Quick Ratio: 10.42

Sales & Book Value

• Annual Sales: $55.23 million
• Price / Sales: 43.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.41 per share
• Price / Book: 15.82

Miscellaneous

• Outstanding Shares: 34,140,000
• Free Float: 33,289,000
• Market Cap: $2.38 billion
• Optionable: Optionable
• Beta: 1.14